CN112438899A - Skin care composition with acne conditioning effect and application thereof - Google Patents
Skin care composition with acne conditioning effect and application thereof Download PDFInfo
- Publication number
- CN112438899A CN112438899A CN202011489872.0A CN202011489872A CN112438899A CN 112438899 A CN112438899 A CN 112438899A CN 202011489872 A CN202011489872 A CN 202011489872A CN 112438899 A CN112438899 A CN 112438899A
- Authority
- CN
- China
- Prior art keywords
- acne
- skin care
- skin
- care composition
- acne conditioning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 118
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 84
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 64
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 30
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003906 humectant Substances 0.000 claims abstract description 9
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 9
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940099563 lactobionic acid Drugs 0.000 claims abstract description 8
- -1 small molecule organic acid Chemical class 0.000 claims abstract description 7
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims abstract description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000022 bacteriostatic agent Substances 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- 239000000043 antiallergic agent Substances 0.000 claims description 4
- 230000000035 biogenic effect Effects 0.000 claims description 4
- PXGZQGDTEZPERC-UHFFFAOYSA-L cyclohexane-1,4-dicarboxylate Chemical compound [O-]C(=O)C1CCC(C([O-])=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-L 0.000 claims description 4
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 4
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 25
- 229960004889 salicylic acid Drugs 0.000 abstract description 25
- 239000011148 porous material Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 15
- 230000007794 irritation Effects 0.000 abstract description 15
- 150000007524 organic acids Chemical class 0.000 abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 11
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 85
- 239000000686 essence Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 239000002994 raw material Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- 210000003780 hair follicle Anatomy 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010027146 Melanoderma Diseases 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 235000014104 aloe vera supplement Nutrition 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010000503 Acne cystic Diseases 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000715846 Sibynophis collaris Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical compound C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- JNFDQAYPZCYWLD-UHFFFAOYSA-N bis[2-(2-ethoxyethoxy)ethyl] cyclohexane-1,4-dicarboxylate Chemical compound CCOCCOCCOC(=O)C1CCC(C(=O)OCCOCCOCC)CC1 JNFDQAYPZCYWLD-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940100524 ethylhexylglycerin Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Abstract
The invention relates to a skin care composition with acne conditioning effect and application thereof. The skin care composition with acne conditioning efficacy comprises the following components in percentage by weight: 1 to 6 percent of modified salicylic acid, 0.1 to 5 percent of small molecular organic acid, 5 to 10 percent of polyalcohol humectant and 80 to 90 percent of water; wherein the small molecule organic acid is gamma-gluconolactone and/or lactobionic acid; the polyalcohol humectant is propylene glycol and dipropylene glycol. The skin care composition has a acne care effect equivalent to that of salicylic acid, is mild in property and low in irritation to skin, can be used as a daily essence or a water aqua, reduces the number of acne blackheads on the skin, or prevents the occurrence of the acne blackheads, reduces the tendency of acne to develop into inflammatory acne, improves the smoothness of the skin, and reduces the number of visible pores on the skin.
Description
Technical Field
The invention relates to the technical field of skin care products, in particular to a skin care composition with an acne conditioning effect and application thereof.
Background
Acne is generally classified into the following categories by symptoms: common acne, conglobation acne, cosmetic acne, fulminant acne, medical acne, rosacea, comedo acne, blackhead acne, cyst, cystic acne, macula, pimple and pustule. The comedo belongs to the category of acne, is non-inflammatory (mild) acne, and is divided into white comedo (closed comedo without head, which looks like yellow-white dots or small pimples, is different in size, is buried in skin, has no opening and does not expose head) and blackhead comedo (open comedo, which looks small and shallow, has an opening and has a black spot at the opening, is formed by oxidation of oil plug, like bean dregs, and the black spot is left in a small pit after being squeezed out). Generally, comedones are closed comedones, while blackheads are open comedones.
The fundamental causes of acne are the major changes of endocrine function in adolescence, the exuberance of sebum secretion, the hyperplasia of hair follicle epithelium and the hyperkeratosis of hair follicle pores, which block the orifice of the tube and cause the imbalance of sebum production and discharge. Mature comedones are produced when these abnormal keratinocytes accumulate and the follicular infundibulum dilates. Sebum is decomposed by bacteria present in the hair follicle (mainly affected by acne bacillus, staphylococcus epidermidis, pityrosporum orbiculare, etc.) to produce free fatty acids which stimulate the hair follicle to cause inflammation, causing the follicle wall to be damaged and ruptured, and the hair follicle contents to enter the dermis, thereby causing an inflammatory response of varying degrees around the hair follicle. Since inflammation promotes the presence of oxygen free radicals, these acids are easily peroxidized and thus easily cause acne, which in turn increases inflammatory attack. Different proteases, especially elastase produced by inflammation, will slowly break the skin barrier (they attack connective tissue matrix, collagen, elastin, etc.), putting the skin in an unbalanced state of excessive keratinization. Oxygen radicals, also produced in the inflammatory process, not only exacerbate inflammation, but also attack all epidermal cells, thus maximizing the extent of skin disorders.
In order to prevent the worsening of acne or alleviate symptoms, skin care products for preventing and treating acne with curative effects can be used in addition to skin cleansing. At present, skin care products specially aiming at acne on the market are few, and common acne removing skin care products have high irritation. For example, the common blackhead drainage liquid/drainage membrane combination can soften the skin cuticle and tear the blackhead by matching with the drainage membrane with strong tearing capability, although the instant effect is good, the method easily causes the side effects of skin barrier damage, large skin pores and the like, and is not a sustainable and long-term acne conditioning method.
Salicylic Acid (SA) is a simple phenolic compound, and is widely used in the fields of medicines due to its various pharmacological activities such as sterilization, antisepsis, anti-inflammation, anti-rheumatism, etc. The salicylic acid is also one of the common functional components of the skin care product, and has the effects of whitening skin, removing acnes and the like when being used on the skin. Salicylic acid is a fat-soluble compound, and has strong irritation to the skin, so that the application of the salicylic acid is limited, the salicylic acid is often added into an emulsion cream system in the past application of skin care products, the salicylic acid is rarely contained in an aqueous essence formula, some essence or aqueous essence formulas on the market contain the salicylic acid, the content is very low, the acne conditioning effect is not good, or a large amount of alcohol or polyalcohol needs to be added into the formula to increase the content of the salicylic acid, and the formula has very poor skin feel and very large irritation. There are also methods to modify salicylic acid to improve the mildness of salicylic acid in application scenes, but the acne care effect of modified salicylic acid is reduced compared with salicylic acid, and the irritation needs to be further improved.
Disclosure of Invention
Based on this, there is a need for a skin care composition having acne conditioning efficacy. The skin care composition has acne caring effect equivalent to salicylic acid, and has mild property and low irritation to skin.
The specific technical scheme is as follows:
a skin care composition with acne conditioning effect comprises the following components in percentage by weight:
wherein the small molecule organic acid is gamma-gluconolactone and/or lactobionic acid;
the polyalcohol humectant is propylene glycol and dipropylene glycol.
In one embodiment, the small molecule organic acid is lactobionic acid.
In one embodiment, the mass ratio of propylene glycol to dipropylene glycol in the polyol humectant is 1: (1-3).
In one embodiment, the modified salicylic acid is selected from at least one of CycloPEEL, Beta-Hydroxyde ACSD, Salsphere Skin smoothening, and BioGenic SA-200.
In one embodiment, the skin care composition with acne conditioning efficacy further comprises the following components in percentage by weight:
1 to 10 percent of penetration enhancer,
0.05% -20% of a soothing anti-allergy agent, and
0.05 to 5 percent of bacteriostatic agent.
In one embodiment, the soothing anti-sensitivity agent is selected from at least one of dipotassium glycyrrhizinate, allantoin, and Symcalmin.
In one embodiment, the penetration enhancer is selected from at least one of pentanediol, hexanediol, bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate, and ethoxydiglycol.
In one embodiment, the pH range of the skin care composition with acne conditioning efficacy is 2.5-6.5.
The invention also provides application of the skin care composition with the acne conditioning effect in preparing a skin care product.
In one embodiment, the skin care product is a serum or a aqua.
Compared with the prior art, the invention has the following beneficial effects:
according to the skin care composition with the acne conditioning effect, the specific small molecular organic acid and the modified salicylic acid are compounded, so that the acne conditioning effect of the composition can be synergistically improved, and the small molecular organic acid has lower irritation than the modified salicylic acid. Meanwhile, the polyalcohol humectant compounded by propylene glycol and dipropylene glycol can further improve the irritation of the small molecular organic acid and the modified salicylic acid, so that the skin care composition is milder and low in irritation, can be used as a daily essence or water aqua, reduces the number of comedones and blackheads on the skin, or prevents the occurrence of the comedones and blackheads, reduces the tendency of the comedones to develop into inflammatory acne, improves the smoothness of the skin, and reduces the number of visible pores on the skin. In addition, the modified salicylic acid content in the composition is high, and the skin feel is fresh and easy to absorb.
Detailed Description
The skin care composition with acne conditioning effect of the present invention and its application are further described in detail with reference to the following specific examples. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The "comedones" of the present invention are primarily non-inflammatory closed comedones and open comedones (i.e., blackheads).
The invention provides a skin care composition with acne conditioning effect, which comprises the following components in percentage by weight:
wherein the small molecular organic acid is gamma-gluconolactone and/or lactobionic acid;
the polyalcohol humectant is propylene glycol and dipropylene glycol.
According to the skin care composition with the acne conditioning effect, the specific small molecular organic acid and the modified salicylic acid are compounded, so that the acne conditioning effect of the composition can be synergistically improved, and the small molecular organic acid has lower irritation compared with the modified salicylic acid. Meanwhile, the polyalcohol humectant compounded by propylene glycol and dipropylene glycol can further improve the irritation of the small molecular organic acid and the modified salicylic acid, so that the skin care composition is milder and low in irritation, can be used as a daily essence or water aqua, reduces the number of comedones and blackheads on the skin, or prevents the occurrence of the comedones and blackheads, reduces the tendency of the comedones to develop into inflammatory acne, improves the smoothness of the skin, and reduces the number of visible pores on the skin. In addition, the modified salicylic acid content in the composition is high, and the skin feel is fresh and easy to absorb.
Further, in the skin care composition with acne conditioning efficacy, the weight percentage of the modified salicylic acid is preferably 2-4%.
Further, in the skin care composition with acne conditioning effect, the weight percentage of the small molecular organic acid is preferably 0.3-1%.
Further, the skin care composition with acne conditioning efficacy comprises the following components in percentage by weight:
in one example, the small molecule organic acid is lactobionic acid.
In one example, the mass ratio of propylene glycol to dipropylene glycol in the polyol humectant is 1: (1-3).
In one example, the modified salicylic acid is selected from at least one of CycloPEEL, Beta-Hydroxyde ACSD, Salsphere Skin smoothening, and BioGenic SA-200.
Wherein CycloPEEL, available from SETHIC, France, is a sub-nanometer cyclodextrin-encapsulated 50% salicylic acid, water-soluble.
Beta-Hydroxyde ACSD, supplied by BASF in Germany, is a molecular structure of salicylic acid and gum arabic molecularly coupled together in a ratio of 50:50, water soluble.
Salsphere Skin smoothening, available from Salvona, is a composition (water, cocamidopropyl dimethylamine, salicylic acid, phenoxyethanol, ethylhexylglycerin) consisting of submicron spheres, about 0.1 to 0.3 microns in diameter, containing a hydrophobic core, surrounded by a hydrophilic cationic shell designed to be slowly released over time, which helps to anchor the microspheres to the Skin and to suspend them in the formulation. Once placed on the skin, the shell slowly melts into the outer layers of the skin, gradually releasing salicylic acid.
BioGenic SA-200, supplier BIOGENICS, the main components are: salicylic acid, dextrin, xanthan gum and amylopectin are high-concentration completely water-soluble salicylic acid by using a special coating solubilization technology, and the content of active ingredients is 36-44%.
Further, the skin care composition with acne conditioning effect also comprises the following components in percentage by weight:
in one example, the skin care composition with acne conditioning efficacy further comprises the following components in percentage by weight:
1 to 3 percent of penetration enhancer,
0.2% -0.6% of a soothing anti-allergy agent, and
0.1 to 1 percent of bacteriostatic agent.
In one example, the soothing anti-sensitivity agent is selected from at least one of dipotassium glycyrrhizinate, allantoin, and Symcalmin (available from Dezhixin, the main constituents including butylene glycol, 1, 2-pentanediol, hydroxyphenylpropionamide benzoic acid, and ascorbyl palmitate). Preferably, the soothing and anti-allergy agent is a combination of dipotassium glycyrrhizinate, allantoin and Symcalmin, and the weight ratio can be 1: (2-6): (2-6).
In one example, the skin care composition with acne conditioning efficacy has a pH range of 2.5-6.5, and preferably a pH range of 3.8-4.8. The pH value in the range can ensure that the formula has certain cutin peeling capacity and simultaneously keeps certain mildness. Too low a pH is potentially irritating to the skin, and too high a pH results in an organic acid that has too poor a exfoliating ability. Further, the pH adjusting agent used to maintain the above pH range is a combination of citric acid-trisodium citrate, which may be 0.1% to 1% by weight in the skin care composition having acne-conditioning effect.
In one example, the penetration enhancer is selected from at least one of pentanediol, hexanediol, bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate (Neosolue-Aqulio, available from NFC), and ethoxydiglycol. Preferably, the penetration enhancer is a combination of pentanediol and bis-diethoxydiol cyclohexane 1, 4-dicarboxylate.
In one example, the bacteriostatic agent is at least one of aloe vera extract, centella asiatica extract, benzalkonium chloride, salicylic acid, hexamidine di (isethionate) salt, and quaternary ammonium salt-73.
Acne-prone skin is characterized by the proliferation of specific bacteria in the pilosebaceous glands, mainly staphylococci (particularly in the superficial layers of the skin) and propionibacteria (gram-positive anaerobic bacteria in the follicular gland channels). Acne propionibacteria produce lipases that can break down sebum triglycerides into free fatty acids that can provoke or maintain hyperkeratinization of the follicular orifice, resulting in the formation of comedones. Staphylococcus epidermidis and staphylococcus aureus secrete elastase, which is also responsible for the development of acne-like lesions of the skin. Thus, normal skin colonization can be restored by the action of inhibiting bacterial proliferation. Preferably, the bacteriostatic agent is at least one of aloe vera extract and centella asiatica extract.
In addition, optionally, the skin care composition with acne conditioning effect can also be added with skin conditioning agents, skin feeling conditioning agents, thickening agents, solubilizing agents, preservatives, aromatic agents and other ingredients commonly used in skin care products.
The invention also provides application of the skin care composition with the acne conditioning effect in preparing skin care products. Further, the skin care product refers to essence or water.
The following are specific examples, and the components used in the examples are all commercially available products unless otherwise specified.
Examples 1 to 9
Examples 1 to 9 provide 9 essence liquids with acne conditioning effects, and the formula thereof is shown in the following table 1 in percentage by mass:
TABLE 1
The preparation method of the essence with the acne conditioning effect comprises the following steps:
(1) uniformly mixing the No. 1 and No. 2 raw materials, adding the No. 3 raw material, heating to 80-85 ℃, and stirring to dissolve the mixture to be in a transparent state;
(2) sequentially adding 4#, 5#, 6#, 8# and 9# raw materials, stirring and dissolving until no particle solution exists; beginning to cool down;
(3) cooling to 45 deg.C, sequentially adding the rest raw materials, and continuously cooling;
(4) cooling to 32 +/-2 ℃, filtering and discharging, and detecting the pH value to be 3.5-5.5.
Comparative example 1
The formula and the preparation method of the essence with the acne conditioning effect are the same as those in example 1, and the main difference is that: mandelic acid is used as small molecular organic acid instead of lactobionic acid.
Comparative example 2
The formula and the preparation method of the essence with the acne conditioning effect are the same as those in example 1, and the main difference is that: dipropylene glycol was not used, only 8% propylene glycol was used.
Example 10
The effect evaluation was performed on the essences with acne conditioning effects of examples 1 to 9 and comparative examples 1 to 3.
Reference example: the formulations of emulsions containing salicylic acid in equal proportions (only emulsion formulations can be added at relatively high levels of addition because of its very low water solubility) are shown in table 2 below:
TABLE 2
Note:
delta MB is cetyl (and) glyceryl stearate (and) PEG-75 stearate (and) ceteth-20 (and) steareth-20, available from GATTEFOSSE, France.
The preparation process comprises the following steps:
(1) heating the raw materials 1#, 2#, 3#, 4#, 5# and 6# to 70-75 ℃, and dissolving and stirring uniformly to obtain an oil phase;
(2) heating the raw materials No. 7, No. 8, No. 9, No. 10 and No. 11 to 75-80 ℃, and stirring and dissolving the raw materials uniformly to obtain a water phase;
(3) adding the oil phase raw material into the water phase raw material, homogenizing to obtain uniform and fine cream, and cooling;
(4) heating the raw materials No. 16, No. 17 and No. 18 to 55-60 ℃ to dissolve the raw materials into a transparent uniform solution for later use;
(5) cooling to 45 deg.C, sequentially adding homogeneous solutions of raw materials No. 12, No. 13, No. 14, No. 15, No. 16, No. 17, and No. 18, stirring, and cooling;
(6) cooling to 32 +/-1 ℃ and discharging.
Acne conditioning efficacy, mildness, skin feel evaluation
Selecting a test population: 120 healthy volunteers were selected, 10 in each group.
Volunteers included criteria: 1) healthy, without any history of skin or systemic disease; 2) male and female are unlimited, age is 20-65 years, skin is dark or yellow or has slight blotchiness; 3) the attitude is serious, and the product can be used persistently; the excluded population is pregnant or lactating women, sensitive skin, those in the test area who have undergone medical cosmetology (laser, chemical exfoliation, botulinum toxin, skin augmentation or skin pulling), and those who have recently suffered sunburn. 4) The facial skin has typical acne-like characteristics and large pores;
the using method comprises the following steps: after face cleaning, the acne conditioning essence or the acne conditioning cream is mixed at a concentration of 1.25uL/cm2The coating was applied to the facial area at a uniform density twice a day. The product was used continuously for 30 days.
The efficacy evaluation method comprises the following steps: done in questionnaire form.
The main evaluation indexes are as follows: 1) the acne removing effect is evaluated according to the following grades: the effect is obvious, the effect is general, and the effect is not in three levels; 2) the irritation index, the evaluation level is: the stimulation is very stimulation (red swelling, stabbing pain, pruritus, desquamation or other serious discomfort symptoms are generated in the using process), moderate stimulation (the discomfort symptoms are very slight and basically not perceived; the discomfort symptoms are not existed in the later period), and no stimulation is generated at all (the whole using process is very comfortable and has no discomfort feeling); 3) the skin feel index is very dislike (sticky, unabsorbed, heavy and the like, poor spreadability), general and very good (fresh, easy to absorb and good spreadability).
Data processing: the product evaluation standard is obtained by three dimensions of acne removing effect, irritation index and skin feeling index. By the percentage of the user's preference as a comparison.
The test results are shown in table 3 below:
TABLE 3
From the data analysis, the conditioning effect of the acne conditioning essence is almost as good as or even more obvious than that of salicylic acid acne conditioning cream in the same proportion, the irritation is far lower than that of the salicylic acid acne conditioning cream containing pure water, and the skin feeling is much better than that of the acne conditioning cream.
Remarking: in the aspect of acne conditioning effect indexes, all indexes are less than 100 percent in sum, because in the test process, some people in the acne conditioning essence liquid group withdraw due to intolerance.
(II) evaluation of pore Conditioning
Selecting a test population: 60 healthy volunteers were selected. The above volunteers were divided into example 1 group and reference example group, each of which was 30 persons.
Volunteers included criteria: 1) healthy, without any history of skin or systemic disease; 2) male and female are unlimited, age is 20-65 years, skin is dark or yellow or has slight blotchiness; 3) the attitude is serious, and the product can be used persistently; excluding those who are pregnant or lactating women, sensitive skin, have undergone medical cosmetology (laser, chemical exfoliation, botulinum toxin, skin infill or skin pull) in the test area, and have recently sunburn; 4) facial skin has typical acne-like features & large pores.
Testing an instrument:
VISIA digital skin analyzer, Canfield, usa;
VISIA facial skin analyzer, i.e., skin image analysis system, imported by the original U.S. via FDA and CE certification in the united states, can perform quantitative analysis of skin characteristics, and the principle of identifying pores is as follows: high-definition photographing is carried out on the face; applying multiple spectral image science and technology: standard white light, ultraviolet light and cross section polarized light, and 3-angle imaging is performed for 3 times; the standard white light is used for forming phases on visible spots, pores, fine lines and the like on the surface of the skin; the pores reflect the dilation and flatness of the sebaceous gland openings because an open pore can be shaded and darker than normal skin color. Generally, the oil skin pores of the loempe are low in score, and particularly, the pores are obvious in the positions blocked by acnes and blackheads.
The using method comprises the following steps: after cleansing, the sample of example 1 or the reference example was set at 1.25uL/cm2The coating was applied to the facial area at a uniform density twice a day. The product was used continuously for 30 days.
The test method comprises the following steps: the room temperature is controlled to be 20 +/-2 ℃, and the Relative Humidity (RH) is controlled to be 55% +/-3%. The testee enters a test environment 30min before the test and waits for the test quietly, and the VISIA is used for detection 30min later, so that smiling lines, a light reflection area, black nevi and hair are avoided in an analysis area as much as possible.
And recording pore values before and after the product is used, wherein the value before the product is used is an initial value, and the value after the product is used is a test value.
Data processing: the VISIA system carries a database, after being photographed, the VISIA system obtains feature counts according to a system algorithm, and the improvement of skin pores is measured by the absolute score change rate displayed by the system, namely:
rate of change ═ (test value-initial value)/initial value × 100%
The test results are shown in table 4 below:
TABLE 4
As can be seen from the above data, the data for 23 pores in the example 1 group was valid, while the data for 16 pores in the reference group was valid, demonstrating that example 1 of the present invention has a better effect than pure salicylic acid in reducing the number of visible pores.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. The skin care composition with the acne conditioning effect is characterized by comprising the following components in percentage by weight:
wherein the small molecule organic acid is gamma-gluconolactone and/or lactobionic acid;
the polyalcohol humectant is propylene glycol and dipropylene glycol.
2. The skin care composition with acne conditioning efficacy according to claim 1 wherein said small molecule organic acid is lactobionic acid.
3. The skin care composition with acne conditioning efficacy according to claim 1, wherein the mass ratio of propylene glycol to dipropylene glycol in said polyhydric alcohol moisturizer is 1: (1-3).
4. A Skin care composition with acne conditioning efficacy according to claim 1 wherein said modified salicylic acid is selected from at least one of CycloPEEL, Beta-Hydroxyde ACSD, Salsphere Skin smoothening and BioGenic SA-200.
5. The skin care composition with acne conditioning efficacy according to any of claims 1 to 4, characterized by further comprising the following components in percentage by weight:
1 to 10 percent of penetration enhancer,
0.05% -20% of a soothing anti-allergy agent, and
0.05 to 5 percent of bacteriostatic agent.
6. The skin care composition having acne conditioning efficacy according to claim 5 wherein said soothing and anti-sensitivity agent is selected from at least one of dipotassium glycyrrhizinate, allantoin and Symcalmin.
7. A skin care composition having acne conditioning efficacy according to claim 5 wherein said penetration enhancer is selected from at least one of pentanediol, hexanediol, bis-diethoxydiethylene glycol cyclohexane 1, 4-dicarboxylate and ethoxydiglycol.
8. The skin care composition with acne conditioning effect according to any of claims 1 to 4 and 6 to 7, characterized in that the pH of the skin care composition with acne conditioning effect is 2.5 to 6.5.
9. Use of the skin care composition with acne conditioning effect according to any of claims 1 to 8 in the preparation of skin care products.
10. The use of claim 9, wherein the skin care product is a serum or lotion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011489872.0A CN112438899A (en) | 2020-12-16 | 2020-12-16 | Skin care composition with acne conditioning effect and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011489872.0A CN112438899A (en) | 2020-12-16 | 2020-12-16 | Skin care composition with acne conditioning effect and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112438899A true CN112438899A (en) | 2021-03-05 |
Family
ID=74740167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011489872.0A Pending CN112438899A (en) | 2020-12-16 | 2020-12-16 | Skin care composition with acne conditioning effect and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112438899A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113318065A (en) * | 2021-05-07 | 2021-08-31 | 西安润玉医疗科技有限公司 | Composite acid and microecological conditioning composition and preparation process thereof |
| CN114652645A (en) * | 2021-04-27 | 2022-06-24 | 上海科黛生物科技有限公司 | Salicylic acid conditioning jelly membrane and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341419A (en) * | 2000-09-04 | 2002-03-27 | 斯普拉施制造公司 | Skin-care composition |
| US20100087403A1 (en) * | 2008-10-03 | 2010-04-08 | Chiou Win L | Topical treatment of skin infection |
| KR20130090169A (en) * | 2012-02-03 | 2013-08-13 | 주식회사 씨앤피차앤박화장품 | Composition for cosmetics |
| CN105769698A (en) * | 2016-04-14 | 2016-07-20 | 曼秀雷敦(中国)药业有限公司 | Cosmetic composition without preservative and application of cosmetic composition |
| US20180360712A1 (en) * | 2015-12-15 | 2018-12-20 | Underskin Farmaceutical Ltda | Cosmetic composition and use thereof |
| CN109771333A (en) * | 2019-01-18 | 2019-05-21 | 德之馨（上海）有限公司 | Salicylic acid solubilising slow releasing composition and its preparation method and application |
| CN110974709A (en) * | 2020-01-07 | 2020-04-10 | 拉芳家化股份有限公司 | Anti-acne composition |
| CN111297715A (en) * | 2019-12-02 | 2020-06-19 | 上海应用技术大学 | Acne-removing toner containing salicylic acid microcapsules and preparation method thereof |
-
2020
- 2020-12-16 CN CN202011489872.0A patent/CN112438899A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1341419A (en) * | 2000-09-04 | 2002-03-27 | 斯普拉施制造公司 | Skin-care composition |
| US20100087403A1 (en) * | 2008-10-03 | 2010-04-08 | Chiou Win L | Topical treatment of skin infection |
| KR20130090169A (en) * | 2012-02-03 | 2013-08-13 | 주식회사 씨앤피차앤박화장품 | Composition for cosmetics |
| US20180360712A1 (en) * | 2015-12-15 | 2018-12-20 | Underskin Farmaceutical Ltda | Cosmetic composition and use thereof |
| CN105769698A (en) * | 2016-04-14 | 2016-07-20 | 曼秀雷敦(中国)药业有限公司 | Cosmetic composition without preservative and application of cosmetic composition |
| CN109771333A (en) * | 2019-01-18 | 2019-05-21 | 德之馨（上海）有限公司 | Salicylic acid solubilising slow releasing composition and its preparation method and application |
| CN111297715A (en) * | 2019-12-02 | 2020-06-19 | 上海应用技术大学 | Acne-removing toner containing salicylic acid microcapsules and preparation method thereof |
| CN110974709A (en) * | 2020-01-07 | 2020-04-10 | 拉芳家化股份有限公司 | Anti-acne composition |
Non-Patent Citations (1)
| Title |
|---|
| 上海泽楷医疗科技有限公司: "秦观水杨酸棉片", 《国产非特殊用途化妆品备案服务平台》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652645A (en) * | 2021-04-27 | 2022-06-24 | 上海科黛生物科技有限公司 | Salicylic acid conditioning jelly membrane and preparation method thereof |
| CN113318065A (en) * | 2021-05-07 | 2021-08-31 | 西安润玉医疗科技有限公司 | Composite acid and microecological conditioning composition and preparation process thereof |
| CN113318065B (en) * | 2021-05-07 | 2023-01-03 | 西安润玉医疗科技有限公司 | Composite acid and microecological conditioning composition and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108030764B (en) | Double-layer cleansing lotion and preparation method thereof | |
| TW508247B (en) | Cosmetic or dermatological topical composition | |
| Mohiuddin | Skin care creams: formulation and use | |
| US11878070B2 (en) | Silk-based moisturizer compositions and methods thereof | |
| Schmitt | Skin-care products | |
| CN112438899A (en) | Skin care composition with acne conditioning effect and application thereof | |
| US20070092475A1 (en) | Methods for enhancing the morphology, tone, texture and/or appearance of skin using a Meadowestolide | |
| JP4398641B2 (en) | Hypoallergenic and non-irritating skin care preparations | |
| KR20190036341A (en) | Cosmetic Composition for Reducing Stickiness and Improving Transparency of Emulsion Formulation | |
| JP5912397B2 (en) | Cosmetic liquid, cosmetic liquid production method and cosmetic method | |
| CN105581916A (en) | Antibacterial and anti-inflammatory mild cleansing cream and preparation method thereof | |
| JPS63280006A (en) | Agent for suppressing irritant feeling of skin and cosmetic containing said agent | |
| KR100371028B1 (en) | Cosmetic composition containing Salvia militiorrhira Bge. extracts and polyethoxylated retinamide | |
| EP1192940A1 (en) | Compositions and methods for promoting clear skin using an alkanolamine | |
| CN105796461A (en) | Moisturizing and repairing lotion containing hydrolyzed pearl essence flexible nano-liposomes and sea buckthron oil | |
| US20050281853A1 (en) | Skin compatible cosmetic compositions and delivery methods therefor | |
| US20010014314A1 (en) | Foot soap composition | |
| WO1996027365A1 (en) | Gentle anti-acne composition | |
| CN111388360A (en) | Bathing essential oil and preparation method thereof | |
| JPH11302147A (en) | Cosmetic | |
| CN112641675B (en) | Blackhead removing composition, application and blackhead removing scrub skin cleaning cream | |
| TWI306764B (en) | Insoluble powder, reviving powder for skin barrier function, powder for preventing and ameliorating coarse skin, troubles, and preparation containing the same for external use | |
| CN114209637B (en) | Soothing composition and application thereof | |
| CN116077361B (en) | Composition with deep skin cleaning effect, preparation method and application | |
| JPS61207326A (en) | Skin treating composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210305 |
|
| RJ01 | Rejection of invention patent application after publication |